Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind sham-controlled trial of Zimura in autosomal recessive Stargardt disease
MOH_2018-06-03_002176Phase 2Completed
- Sponsor
- IVERIC bio
- Start
- May 2018
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of avacincaptad pegol in ABCA4-related Stargardt disease (STGD1) (2 arms), sponsored by IVERIC bio. Started May 2018; status: completed.
02
Drugs
avacincaptad pegol
03
Conditions
ABCA4-related Stargardt disease (STGD1)
Beyond the preview
Go deeper on MOH_2018-06-03_002176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-06-03_002176.